Figure 2. Sensitivity Analysis: Incremental Cost-Effectiveness of a Novel 4-Month Regimen in a Low Treatment Cost Scenario.

The vertical line corresponds to the estimated incremental cost-effectiveness ratio (ICER) of a four-month regimen, relative to the standard (six-month) regimen, in the low cost scenario ($740 per disability-adjusted life year [DALY] averted, Table 2). Black bars represent the high value of each parameter, as listed in Table 1 (e.g., 0.3 for probability of death on recurrence); white bars represent the low value (e.g., 0.04). Bars to the left represent more favorable ratios for the four-month regimen; sensitivity ranges of the delivery cost and new regimen cost were truncated at the point where they become cost-saving (i.e., ICER = 0). Only those parameters for which sensitivity analysis changed the estimated ICER by $200 in either direction are shown.